Figure Meta-analysis of 9 studies of patients with attention-deficit/hyperactivity disorder (ADHD) vs controls Meta-analysis of 9 studies of patients with.

Slides:

Advertisements

Similar presentations

Figure Pedigrees of the SCA42 families identified in this study

Advertisements

مقدمة: الاطفال الذين يعانون من كثرة النشاط الحركى ليسوا باطفال مشاغبين، او عديمين التربية لكن هم اطفال عندهم مشكلة مرضية لها تاثير سيء على التطور النفسى.

Figure Flow of funds for a 340B agreement for fingolimod

Figure 1 Summary of prior diagnostic workup in neuromuscular disorder cases Summary of prior diagnostic workup in neuromuscular disorder cases Percentage.

Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.

Figure 1 Box plot of the venous diameter in lesions

Figure 2 Needle biopsy of the left vastus lateralis

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.

Figure 3 JCV index changes in JCV+ patients

Figure 2 FXTAS Rating Scale scores for case 1

Figure Pedigree of the family

Figure 2 Association between coronary artery disease polygenic risk score and the presence of migraine Results are given as odds ratios with 95% confidence.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.

Figure 2 Provider decision algorithm: Considerations in retirement discussion and recommendation Provider decision algorithm: Considerations in retirement.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 2 Luciferase assays of transiently transfected HEK 293 cells with reporter constructs containing the 766-bp wild-type KCNJ18 or c.-542 T/A mutant.

Figure 2. EZO levels in infants and young children compared to adults at similar doses EZO levels in infants and young children compared to adults at similar.

Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer

Figure Association of hippocampal subfield volumes to cognition by neopterin level, volumes, and cognition adjusted for age, education, race, sex, and.

Figure 1 Dominant and recessive missense and nonsense variants in neurofilament light (NEFL)‏ Dominant and recessive missense and nonsense variants in.

Figure 2 Forest plots for subgroup analyses

Figure 3 Temporal trends in FALS incidence

Figure 1 All patients with pediatric genetic movement disorders, their genetic diagnoses, and type of genetic investigations All patients with pediatric.

Figure 5 Neurite structure is not disrupted by the lack of neurofilament light (NEFL)‏ Neurite structure is not disrupted by the lack of neurofilament.

Figure 2 Linkage analysis of chromosome 19

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Figure Genetic deletion and MRI changes with EHMT1 deletion

Figure 1 Within-groups sum of squares vs number of clusters Within-groups sum of squares vs number of clusters to determine the number needed for k-means.

Table 2 Rs number, gene, OR, 95% CI, and permutation p value for the statistical significant variants resulted from allelic association analysis association.

Figure 4 Voltage-clamp recordings of KCNJ18 carrying the patient's SNVs expressed in Xenopus laevis oocytes under control conditions and after application.

Figure Diagrammatic levodopa pharmacokinetics after single doses of immediate release (IR) carbidopa/levodopa (CD/LD) and 3 strengths of extended release.

Figure 1 JCV serostatus JCV serostatus (A) Serostatus of 1,921 natalizumab-treated patients with multiple sclerosis, with JCV− patients shown in black.

Figure 4. Electron microscopic findings in AP-5 patient cells

Figure 1 Annual trend in specimen type submitted as first sample for aquaporin-4 immunoglobulin G testing (serum only vs CSF only vs both) from 101,065.

Figure 5 Autopsy Mycoplasma DNA analysis

Figure 1 Examples illustrating gating strategy for fluorescence-activated cell sorting (FACS)‏ Examples illustrating gating strategy for fluorescence-activated.

Figure 1 Association between serum levels of IL-18 and hippocampal volume in patients with schizophrenia Scatter plots show a positive correlation between.

Figure 2 Correlation of CSF 8-iso-PGF2α levels with other indicators of oxidative stressCorrelations of 8-iso-prostaglandin F2α (8-iso-PGF2α) values with.

Figure 1 Histamine flare in patients and controls

Figure 1 Percentage distribution according to severity of baseline behavioral changes in behavioral variant frontotemporal dementia (bvFTD) and semantic.

Figure Molecular structure Molecular structure of delta-9-tetrahydrocannabiol (THC) (left), which has psychoactive properties, compared to molecular structure.

Figure 1 Considerations for concussed athletes leading to medical care or return to sport (RTS)‏ Considerations for concussed athletes leading to medical.

Figure 2 Correlation between wGRS and age at onset The figure shows the correlation between weighted genetic risk score (wGRS) and age at onset in all.

Figure 2. Patient stratification by the reported duration of symptoms and disease severity at the time of assessment Patient stratification by the reported.

Figure 2 Global tau-PET distribution in familial prion disease mirrors the distribution seen in Alzheimer disease Global tau-PET distribution in familial.

Figure 2 Quality stages by disorder The x-axis lists each of the quality improvement and practice-based research projects in order of implementation at.

Figure 4. The N:M ratio is significantly increased in patients with ALS and correlates with disease progression The N:M ratio is significantly increased.

Figure 1 Annualized percentage brain volume change

Figure 2 BVL according to on-study disability worsening

Figure 2 Repopulation of CD19+ cells in low and high BSA patients and calculation of the BSA Repopulation of CD19+ cells in low and high BSA patients and.

Figure 1 Our quality journey Quality improvement and practice-based research in neurology using the electronic medical record (EMR) consists of a stepwise.

Figure Spinal cord imaging (A, B) Sagittal and axial T2-weighted cervical spine MRI demonstrating hyperintensities in the central gray matter of patient.

Figure 1 bvFTD PINBPA network

Figure 2 Seizure outcomes

Figure 1 Classical pathway and lectin pathway activity in patients with multifocal motor neuropathy and controls Classical pathway (CP) activity (A) and.

Increase in adults treated at children's hospitals, 1999–2012, according to age group. Increase in adults treated at children's hospitals, 1999–2012, according.

Figure Interactive world map

Yian Gu et al. Neurol Neuroimmunol Neuroinflamm 2019;6:e521

Ingo Kleiter et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e504

Figure 6 Multiple target epitopes exist in the N-terminal domains of Caspr2 (A) Multidomain deletion constructs of Caspr2 were generated to determine which.

Gitanjali Das et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e453

Figure 2 Model representations of performance on functional and behavioral measures over time for behavioral variant frontotemporal dementia (bvFTD) and.

Figure 3 Within-group comparisons (before–after)‏

Figure 2 Striatal dopamine transporter binding with the SNCA A53E mutation Transaxial planes of [123I]FP-CIT SPECT on the striatal level are presented.

Socio-demographic data

Figure 2. Percentage of CD16− monocytes in the blood is reduced during disease progression Percentage of CD16− monocytes in the blood is reduced during.

White Matter by Diffusion MRI following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-Deficit/Hyperactivity Disorder In.

Figure (A and B) Effect of canakinumab in muscle strength measured in each patient as mean bilateral GF (A) and TMS (B) during the mean study period of.

Presentation transcript:

Figure Meta-analysis of 9 studies of patients with attention-deficit/hyperactivity disorder (ADHD) vs controls Meta-analysis of 9 studies of patients with attention-deficit/hyperactivity disorder (ADHD) vs controls Two age groups are presented: younger children (age 6–13; A) and all children (age 6–18; B). Theta/beta ratio (TBR) means and SDs are presented. The 9 studies are shown chronologically as published. Note how the differences between ADHD and controls narrowed over time, and how much scatter is seen in TBR measurements among studies of younger children. From Arns et al.12 Marc R. Nuwer et al. Neurol Clin Pract 2016;6:543-548 © 2016 American Academy of Neurology